Cell surface antibody-associated neurodegeneration: The case of anti-IgLON5 antibodies

Affiliations

¹ From the Institute for Neuroscience and Muscle Research (R.C.D., S.R.), University of Sydney; Children's Hospital at Westmead (R.C.D.); and Westmead Hospital (S.R.), Sydney, Australia. Russell.dale@health.nsw.gov.au.
² From the Institute for Neuroscience and Muscle Research (R.C.D., S.R.), University of Sydney; Children's Hospital at Westmead (R.C.D.); and Westmead Hospital (S.R.), Sydney, Australia.

Editorial

Russell C Dale et al. Neurology. 2017.

. 2017 May 2;88(18):1688-1690.

doi: 10.1212/WNL.0000000000003931. Epub 2017 Apr 5.

¹ From the Institute for Neuroscience and Muscle Research (R.C.D., S.R.), University of Sydney; Children's Hospital at Westmead (R.C.D.); and Westmead Hospital (S.R.), Sydney, Australia. Russell.dale@health.nsw.gov.au.
² From the Institute for Neuroscience and Muscle Research (R.C.D., S.R.), University of Sydney; Children's Hospital at Westmead (R.C.D.); and Westmead Hospital (S.R.), Sydney, Australia.

No abstract available

Comment on

Clinical manifestations of the anti-IgLON5 disease.
Gaig C, Graus F, Compta Y, Högl B, Bataller L, Brüggemann N, Giordana C, Heidbreder A, Kotschet K, Lewerenz J, Macher S, Martí MJ, Montojo T, Pérez-Pérez J, Puertas I, Seitz C, Simabukuro M, Téllez N, Wandinger KP, Iranzo A, Ercilla G, Sabater L, Santamaría J, Dalmau J. Gaig C, et al. Neurology. 2017 May 2;88(18):1736-1743. doi: 10.1212/WNL.0000000000003887. Epub 2017 Apr 5. Neurology. 2017. PMID: 28381508 Free PMC article.